Citadel Advisors’s Blueprint Medicines BPMC Stock Holding History

Citadel Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-71,000	Closed	-$9.1M	–	12798
2025 Q2	$9.1M	Sell	71,000 -2,400	-3%	-$249K	﹤0.01%	3165
2025 Q1	$6.5M	Sell	73,400 -6,100	-8%	-$595K	﹤0.01%	3476
2024 Q4	$6.93M	Sell	79,500 -38,400	-33%	-$3.52M	﹤0.01%	3458
2024 Q3	$10.9M	Sell	117,900 -44,500	-27%	-$4.42M	﹤0.01%	2770
2024 Q2	$17.5M	Buy	162,400 +43,600	+37%	+$4.36M	﹤0.01%	2134
2024 Q1	$11.3M	Buy	118,800 +18,300	+18%	+$1.57M	﹤0.01%	2792
2023 Q4	$9.27M	Buy	100,500 +86,700	+628%	+$5.62M	﹤0.01%	2954
2023 Q3	$693K	Buy	13,800 +7,300	+112%	+$390K	﹤0.01%	7363
2023 Q2	$411K	Sell	6,500 -3,800	-37%	-$207K	﹤0.01%	8357
2023 Q1	$463K	Sell	10,300 -7,000	-40%	-$315K	﹤0.01%	8475
2022 Q4	$758K	Sell	17,300 -45,900	-73%	-$2.2M	﹤0.01%	7374
2022 Q3	$4.16M	Sell	63,200 -82,200	-57%	-$5.28M	﹤0.01%	4179
2022 Q2	$7.34M	Buy	145,400 +137,200	+1,673%	+$8.04M	﹤0.01%	3121
2022 Q1	$524K	Buy	8,200 +2,500	+44%	+$179K	﹤0.01%	9278
2021 Q4	$611K	Buy	5,700 +1,000	+21%	+$105K	﹤0.01%	9186
2021 Q3	$483K	Sell	4,700 -3,100	-40%	-$289K	﹤0.01%	9952
2021 Q2	$686K	Sell	7,800 -3,100	-28%	-$284K	﹤0.01%	9285
2021 Q1	$1.06M	Sell	10,900 -8,600	-44%	-$859K	﹤0.01%	7966
2020 Q4	$2.19M	Sell	19,500 -8,500	-30%	-$896K	﹤0.01%	5176
2020 Q3	$2.6M	Sell	28,000 -1,900	-6%	-$146K	﹤0.01%	4244
2020 Q2	$2.33M	Sell	29,900 -7,400	-20%	-$501K	﹤0.01%	4306
2020 Q1	$2.18M	Buy	37,300 +1,100	+3%	+$70.8K	﹤0.01%	3999
2019 Q4	$2.9M	Sell	36,200 -105,800	-75%	-$7.92M	﹤0.01%	3828
2019 Q3	$10.4M	Buy	142,000 +121,100	+579%	+$10.5M	﹤0.01%	2169
2019 Q2	$1.97M	Sell	20,900 -8,000	-28%	-$660K	﹤0.01%	4533
2019 Q1	$2.31M	Buy	28,900 +5,500	+24%	+$406K	﹤0.01%	4218
2018 Q4	$1.26M	Sell	23,400 -6,600	-22%	-$401K	﹤0.01%	4938
2018 Q3	$2.34M	Buy	30,000 +9,400	+46%	+$653K	﹤0.01%	4140
2018 Q2	$1.31M	Buy	20,600 +6,100	+42%	+$485K	﹤0.01%	4765
2018 Q1	$1.33M	Sell	14,500 -3,400	-19%	-$293K	﹤0.01%	4370
2017 Q4	$1.35M	Sell	17,900 -11,500	-39%	-$809K	﹤0.01%	4200
2017 Q3	$2.05M	Sell	29,400 -17,400	-37%	-$930K	﹤0.01%	3383
2017 Q2	$2.37M	Buy	46,800 +38,900	+492%	+$1.65M	﹤0.01%	2949
2017 Q1	$316K	Buy	+7,900	New	+$283K	﹤0.01%	5806
2016 Q1	–	Sell	-3,000	Closed	-$79K	–	6816
2015 Q4	$79K	Sell	3,000 -1,800	-38%	-$40.5K	﹤0.01%	6924
2015 Q3	$102K	Buy	+4,800	New	+$133K	﹤0.01%	6938

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's BPMC Position: Q3 2025 in Review

Citadel Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 25,094 shares — an estimated $3.22M sold.

Citadel Advisors first reported a position in BPMC in Q2 2015 and held it in 36 quarters. The position peaked at $56.7M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Citadel Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 25,094 Blueprint Medicines shares in Q3 2025, an estimated $3.22M.
Citadel Advisors first reported a position in Blueprint Medicines in Q2 2015 and held it in 36 quarters.
Citadel Advisors's Blueprint Medicines position peaked at $56.7M in Q4 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.